Phenylketonuria (PKU) and Cystic Fibrosis (CF) have an incidence in Northern Ireland of 1 : 4000 and 1: 2000 respectively (1994 figures). Management problems are dietary, disease-related and psychological. Search of the literature has revealed no previous report of a child with both conditions. We present the case of a child in whom both CF and PKU were identified on routine neonatal screening. The case highlights the value of this procedure. Case Report A female infant weighing 3370 g was born by normal delivery at 39 weeks gestation to parents who believed that they were distantly related. They had one other child, a female, aged five years who was alive and well. There were no perinatal problems but an abnormal phenylalanine result from routine neonatal Guthrie card screening was confirmed by a plasma phenylalanine concentration of 934 mcmol/l on the fourteenth day (normal range 64-92 mcmol/l). Urinary phenylalanine was elevated at 45 mcmol/l (normal range 4-17 mcmol/l) and urinary phenylalanine excretion was 163 mcmol/mmol creatinine. Protein, ketoacids and phenylketones were absent from the urine. PKU was diagnosed and she was commenced on XP Analog (Scientific Hospital Supplies) together with 60 ml SMA Gold Cap (Wyeth) for 3 days increasing to 210 ml SMA Gold Cap to provide a small but essential amount of phenylalanine. By 5 weeks of age concern was expressed about a poor weight gain of 90 g from birth. Neonatal screening had confirmed high immunoreactive trypsin and subsequent sweat tests revealed raised sodium concentration of 104 mmol/l. At 7 weeks she was admitted to hospital for assessment and management of CF. There were no respiratory symptoms but stools were loose and foul-smelling. Serum vitamin A was low at 0.61 mcmol/l (normal range 1.1-3.5 mcmol/l), and serum vitamin E at 5.23 mcmol/l (normal range 16-35 mcmol/l).
Nutrizym GR(3) (Merck), flucloxacillin, and vitamin supplements including vitamin E were prescribed and physiotherapy commenced three times daily. There was an increase in height and weight velocity ( Figure 1 ) and phenylalanine tolerance fell (Figure 2 ) following the commencement of pancreatic enzyme replacement therapy. At the age of eight months she was admitted with a lower respiratory tract infection for intensive physiotherapy. Prophylaxis with Augmentin suspension, an aspartame-containing antibiotic (7.0 15 mg phenylalanine/5 ml), was inadvertently prescribed for six weeks although the dosage was low (7.5 ml daily) and unlikely to have affected phenylalanine control significantly. Genotype analysis has shown that she is homozygous for delta F 508, and also shows the PKU mutations R408W, Y414C. At the age of twenty-eight months she is making good progress with normal development. 
